Breaking News Instant updates and real-time market news.

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

, KITE

Kite Pharma

$50.76

0.04 (0.08%)

21:25
12/03/16
12/03
21:25
12/03/16
21:25

Canaccord biotech analyst to hold a dinner meeting

In conjunction with the 58th Annual ASH Meeting, Biotech Analyst Newman hosts a Key Opinion Leader Dinner Meeting with Jae Park, MD, who discusses the implications for Juno Therapeutics (JUNO), Kite Pharma (KITE), bluebird bio (BLUE) and Novartis (NVS), on December 3 at 10 pm.

JUNO

Juno Therapeutics

$20.43

0.53 (2.66%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

BLUE

bluebird bio

$69.75

1.1 (1.60%)

NVS

Novartis

$68.17

0.42 (0.62%)

  • 03

    Dec

  • 03

    Dec

JUNO Juno Therapeutics
$20.43

0.53 (2.66%)

12/01/16
LEER
12/01/16
NO CHANGE
LEER
Outperform
bluebird bio data looks 'impressive,' says Leerink
Leerink analyst Michael Schmidt notes that bluebird bio (BLUE) announced first clinical data from its ongoing Phase I study of anti-BCMA CAR-T product candidate "bb2121" in relapsed/refractory multiple myeloma, and says it looks 'impressive." While he cautions that the data is still "somewhat immature," the early results justify the high level of excitement around the potential of anti-BCMA CAR-T therapy in relapsed/ refractory myeloma, as several other companies including Juno Therapeutics (JUNO), Kite Pharma (KITE) and Novartis (NVS) have stated plans to also develop anti-BCMA-CART product candidates. Schmidt reiterates an Outperform rating on bluebird bio's shares.
11/25/16
MAXM
11/25/16
NO CHANGE
Target $34
MAXM
Buy
Juno still has significant opportunity in 'no-option population,' says Maxim
Maxim analyst Jason McCarthy removed JCAR015 in adult ALL from his model for Juno Therapeutics after the company placed its ROCKET study on clinical hold for the second time following two additional patient deaths. Accordingly, the analyst lowered his price target on Juno shares to $34 from $50. However, McCarthy keeps a Buy rating on Juno shares, as he still believes CAR-T technology, and the company, has a "significant opportunity in the no-option population" and that regulators will agree when evaluating treatments intended to help patients that will otherwise die.
11/28/16
LEER
11/28/16
NO CHANGE
Target $34
LEER
Outperform
Juno Therapeutics price target lowered to $34 from $45 at Leerink
Leerink analyst Michael Schmidt lowered his price target for Juno Therapeutics to $34 from $45 following news that the pivotal ROCKET trial of its JCAR015 product candidate in adult acute lymphocytic leukemia has been placed on a clinical hold due to safety concerns. The analyst believes the future of the program is now increasingly uncertain as the company's management is trying to better understand the therapeutic window of JCAR015, raising the question of whether it moved into a pivotal trial too fast. Schmidt reiterates an Outperform rating on the shares.
11/29/16
ADAM
11/29/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma benefits from program delays at Juno, says Canaccord
Canaccord analyst John Newman believes Kite Pharma (KITE) will benefit from the program delays at Juno Therapeutics (JUNO). Two deaths in Juno's Phase 2 ROCKET trial may prompt safety questions for its drug to be used in refractory NHL, which raises the upside potential for Kite when its presents its data at the ASH conference. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
KITE Kite Pharma
$50.76

0.04 (0.08%)

11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
BLUE bluebird bio
$69.75

1.1 (1.60%)

12/01/16
PIPR
12/01/16
NO CHANGE
PIPR
Overweight
bluebird bio BCMA CAR-T results early, but encouraging, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer noted that bluebird bio's interim data from its ongoing Phase 1 study of bb2121, the company's investigational anti-BCMA CAR-T candidate in patients with relapsed/refractory multiple myeloma, showed that four of nine patients achieved partial responses and two patients achieved stringent complete responses. While results are early, they are also encouraging, said Schimmer, who has an Overweight rating on bluebird shares.
12/01/16
BMOC
12/01/16
NO CHANGE
BMOC
bluebird bio data 'impressive,' says BMO Capital
BMO Capital analyst Matthew Luchini says that bluebird bio's Phase I data for its bb2121 product in myeloma was "impressive." The analyst notes that the overall response rate was 78%, and he adds the product to his model for the company ,estimating peak sales of about $3.6B. However, he keeps a Market Perform rating on the shares, citing the approximately 25% increase in the stock in after-hours trading.
12/02/16
MAXM
12/02/16
NO CHANGE
Target $87
MAXM
Buy
bluebird bio price target raised to $87 from $57 at Maxim
Maxim analyst Jason McCarthy said the early data on bluebird bio's bb2121 show it is inducing clinical responses, including complete responses, "essentially in the absence of" CRS and neuro-toxicity. While waiting to see if this trend continues, given the positive bb2121 data so far in multiple myeloma, McCarthy raised his price target on bluebird shares to $87 from $57. He keeps a Buy rating on the stock, noting that he is now factoring in a bb2121 launch in 2021.
NVS Novartis
$68.17

0.42 (0.62%)

11/10/16
ARGS
11/10/16
UPGRADE
ARGS
Buy
Novartis upgraded to Buy from Hold at Argus
11/10/16
11/10/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Priceline (PCLN) upgraded to Buy from Hold at Stifel while the firm upgraded Expedia (EXPE) to Hold from Sell. 2. IBM (IBM) upgraded to Buy from Neutral at BofA/Merrill with analyst Wamsi Mohan expecting 2017 profits to grow as earnings have stabilized and negative revisions are unlikely and expects tailwinds from moderating pace of investments and savings from restructuring efforts. 3. L-3 Communications (LLL) and Northrop Grumman (NOC) upgraded to Overweight from Equal Weight at Barclays while the firm upgraded Lockheed Martin (LMT) to Equal Weight from Underweight. 4. Microsoft (MSFT) upgraded to Neutral from Underweight at Atlantic Equities. 5. Novartis (NVS) upgraded to Buy from Hold at Argus. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/30/16
RHCO
11/30/16
NO CHANGE
RHCO
GlycoMimetics has positive read through from deal, says SunTrust
SunTrust analyst Yatin Suneja says that Novartis' (NVS) recent acquisition of Selexys Pharmaceuticals "provides further clinical and commercial validation for the selectin class of adhesion molecules as meaningful therapeutic targets." The analyst notes that the acquisition came after Selexys' SelG1, which utilizes a P-selectin antibody, showed positive Phase II data in sickle cell disease. GlycoMimetics (GLYC) develops selectin antagonists. The analyst expects interest in the name to accelerate as more data is announced. Suneja keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

KPTI

Karyopharm

$9.96

0.46 (4.84%)

06:32
06/23/17
06/23
06:32
06/23/17
06:32
Hot Stocks
Karyopharm reports updated Phase 2b SADAL data for selinexor »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

DFIN

Donnelley Financial Solutions

$21.66

-0.41 (-1.86%)

06:27
06/23/17
06/23
06:27
06/23/17
06:27
Initiation
Donnelley Financial Solutions initiated  »

Donnelley Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLD

Prologis

$57.64

-0.41 (-0.71%)

06:24
06/23/17
06/23
06:24
06/23/17
06:24
Upgrade
Prologis rating change  »

Prologis upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRE

Duke Realty

$28.28

-0.22 (-0.77%)

06:24
06/23/17
06/23
06:24
06/23/17
06:24
Downgrade
Duke Realty rating change  »

Duke Realty downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

, WFM

Whole Foods

$43.20

-0.06 (-0.14%)

06:23
06/23/17
06/23
06:23
06/23/17
06:23
Periodicals
Some believe Whole Foods would give Amazon 'unfair advantage,' Reuters says »

Antitrust experts believe…

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

WFM

Whole Foods

$43.20

-0.06 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

06:21
06/23/17
06/23
06:21
06/23/17
06:21
Technical Analysis
Technical View: Bed Bath & Beyond tumbles after earnings miss expectations »

The company reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

NAP

Navios Maritime Midstream

$9.88

0.13 (1.33%)

06:19
06/23/17
06/23
06:19
06/23/17
06:19
Downgrade
Navios Maritime Midstream rating change  »

Navios Maritime Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

06:19
06/23/17
06/23
06:19
06/23/17
06:19
Periodicals
Waymo hires former Tesla engineer to lead hardware team, Bloomberg says »

Alphabet's (GOOG,…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

TSLA

Tesla

$382.61

6.21 (1.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 02

    Oct

TSN

Tyson Foods

$61.72

0.34 (0.55%)

06:16
06/23/17
06/23
06:16
06/23/17
06:16
Hot Stocks
Tyson Foods to invest $49M to expand Macon, GA distribution center »

Tyson Foods, Inc. is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAIN

Hain Celestial

$32.66

-0.5 (-1.51%)

06:15
06/23/17
06/23
06:15
06/23/17
06:15
Downgrade
Hain Celestial rating change  »

Hain Celestial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

BA

Boeing

$199.44

0.27 (0.14%)

, EADSY

Airbus

$20.80

-0.07 (-0.34%)

06:14
06/23/17
06/23
06:14
06/23/17
06:14
Periodicals
Boeing announces layoffs at 787 Dreamliner campus, Post and Courier says »

Boeing (BA) is cutting…

BA

Boeing

$199.44

0.27 (0.14%)

EADSY

Airbus

$20.80

-0.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.40

-0.51 (-0.33%)

, MSFT

Microsoft

$70.26

-0.01 (-0.01%)

06:12
06/23/17
06/23
06:12
06/23/17
06:12
Periodicals
LinkedIn CEO: Sandberg seems 'quite happy' at Facebook, NY Post reports »

Jeff Weiner, the CEO of…

FB

Facebook

$153.40

-0.51 (-0.33%)

MSFT

Microsoft

$70.26

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

  • 20

    Jul

SKT

Tanger Factory

$25.70

0.48 (1.90%)

06:11
06/23/17
06/23
06:11
06/23/17
06:11
Downgrade
Tanger Factory rating change  »

Tanger Factory downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$20.80

-0.07 (-0.34%)

06:09
06/23/17
06/23
06:09
06/23/17
06:09
Periodicals
Airbus' sales chief Leahy may retire before Dubai Airshow, Reuters reports »

John Leahy, Airbus'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

, TWTR

Twitter

$18.15

0.37 (2.08%)

06:07
06/23/17
06/23
06:07
06/23/17
06:07
Periodicals
Amazon wants to sell Thurs. Night Football ad deals for $2.8M each, Reuters says »

Amazon (AMZN) wants to…

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

TWTR

Twitter

$18.15

0.37 (2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

F

Ford

$11.13

0.09 (0.82%)

06:05
06/23/17
06/23
06:05
06/23/17
06:05
Periodicals
Ford recalling nearly 16,000 cars in South Africa due to fire risk, Reuters says »

Ford is recalling almost…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

ENOC

EnerNOC

$7.65

2.25 (41.67%)

06:05
06/23/17
06/23
06:05
06/23/17
06:05
Downgrade
EnerNOC rating change  »

EnerNOC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$154.40

0.61 (0.40%)

06:05
06/23/17
06/23
06:05
06/23/17
06:05
Hot Stocks
IBM achieves climate protection goals four years early »

IBM announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVHY

Vivendi

$22.76

-0.105 (-0.46%)

06:04
06/23/17
06/23
06:04
06/23/17
06:04
Upgrade
Vivendi rating change  »

Vivendi upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$103.84

0.37 (0.36%)

06:04
06/23/17
06/23
06:04
06/23/17
06:04
Downgrade
Caterpillar rating change  »

Caterpillar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$104.22

-0.58 (-0.55%)

, GOOG

Alphabet

$957.09

-2.36 (-0.25%)

05:59
06/23/17
06/23
05:59
06/23/17
05:59
Periodicals
Spotify names Staggs, Warrior to board; Parker leaves board, TechCrunch says »

Spotify has appointed…

DIS

Disney

$104.22

-0.58 (-0.55%)

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

CSCO

Cisco

$31.85

0.01 (0.03%)

P

Pandora

$7.80

0.29 (3.86%)

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

AAPL

Apple

$145.63

-0.24 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 28

    Jun

  • 12

    Jul

  • 19

    Jul

  • 08

    Aug

  • 16

    Aug

SPX

S&P 500

05:55
06/23/17
06/23
05:55
06/23/17
05:55
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$86.34

3.78 (4.58%)

05:52
06/23/17
06/23
05:52
06/23/17
05:52
Hot Stocks
Novartis Kisqali receives CHMP opinion as first-line treatment for HR+/HER2- »

Novartis announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

GDX

Market Vector Gold Miners

$22.36

0.25 (1.13%)

05:51
06/23/17
06/23
05:51
06/23/17
05:51
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.92

0.4 (0.34%)

05:50
06/23/17
06/23
05:50
06/23/17
05:50
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.